Alzheon returns, with a $47M NIH grant and one last shot at a pivotal PhIII Alzheimer’s success
Alzheon has spent four years searching for investors, public or private, willing to back a large study for their once-failed Alzheimer’s drug. On Thursday, they …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
